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The ability of dendritic cells (DCs) to activate immunity is linked to their maturation status.
In prior studies, we have shown that selective antibody-mediated blockade of inhibitory
Fc𝛄RIIB receptor on human DCs in the presence of activating immunoglobulin (Ig) ligands
leads to DC maturation and enhanced immunity to antibody-coated tumor cells. We show
that Fc𝛄 receptor (Fc𝛄R)–mediated activation of human monocytes and monocyte-derived
DCs is associated with a distinct gene expression pattern, including several inflammationassociated chemokines, as well as type 1 interferon (IFN) response genes, including the
activation of signal transducer and activator of transcription 1 (STAT1). Fc𝛄R-mediated
STAT1 activation is rapid and requires activating Fc𝛄Rs. However, this IFN response is
observed without a detectable increase in the expression of type I IFNs themselves or the
need to add exogenous IFNs. Induction of IFN response genes plays an important role in
Fc𝛄R-mediated effects on DCs, as suppression of STAT1 by RNA interference inhibited Fc𝛄Rmediated DC maturation. These data suggest that the balance of activating/inhibitory
Fc𝛄Rs may regulate IFN signaling in myeloid cells. Manipulation of Fc𝛄R balance on DCs
and monocytes may provide a novel approach to regulating IFN-mediated pathways in
autoimmunity and human cancer.
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The FcγR system comprises both activating and
inhibitory receptors, and the balance of these two
types of receptors determines the outcome of
immune complex (IC)–mediated inflammation,
immunity, and antibody-based immunotherapy
(1). Altering this balance by using a selective
blocking antibody against the human inhibitory
FcγRIIB receptor in the presence of activating Ig
ligands in human plasma leads to enhanced generation of antitumor T cell responses (2). Mice deficient in the inhibitory FcγR FcγRII also show
enhanced T cell immunity to model antigens (3).
However, the mechanisms by which activating
FcγRs mediate maturation of human DCs and enhance adaptive immunity remain to be clarified.
IFNs are pleiotropic cytokines with potent
antiviral, antitumor, growth suppressive, and
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immunomodulatory properties (4). The cellular effects of both type I (IFN-α and -β) and
type II (IFN-γ) IFNs are mediated via activation of the STAT family of transcription factors
and downstream activation of a distinct set of
“IFN response genes” (IRGs) (5). IFNs play an
important role in the regulation of both innate
and adaptive immunity (6). For example, IFNs
play a critical role in T cell–dependent antibody responses to antigens delivered with the
classical complete Freund’s adjuvant, DNA vaccines, and immunostimulatory DNA (7–9), and
they promote the induction of cytotoxic T cells
in vivo (10, 11). IFN-mediated signaling pathways also play an important role in immune
surveillance and protection from tumors (12).
Dysregulation of IFN signaling has been observed in patients with several autoimmune diseases (6, 13). Therefore, pathways that regulate
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RESULTS
A distinct gene expression profile (GEP) of DCs treated
with anti-Fc𝛄RIIB antibody
We have previously shown that treatment of monocytederived immature DCs (IDCs) with an anti-FcγRIIB–blocking
antibody in the presence of Ig ligands in normal human
plasma leads to DC maturation and enhancement of antitumor T cell immunity (2). To further characterize FcγRmediated enhancement of DC function, we analyzed the
GEPs of pure populations of monocyte-derived DCs (MoDcs) from healthy donors (n = 5) using Affymetrix Human
Genome U133 Plus 2.0 microarrays. IDCs cultured in 1%
plasma were treated for 24 h with either anti-FcγRIIB or
isotype control antibody. To test whether FcγR-mediated
DC maturation was distinct from other maturation stimuli,
we also compared DCs matured using the infl ammatory cytokine cocktail (TNF-α, IL-1β, IL-6, and PGE2) that is
commonly used in DC immunotherapy trials (15). To first
validate the GEP data at the protein level, we compared the
gene expression data for some of the genes associated with
DC maturation (CD83 and CD80) with the detection of
corresponding proteins by flow cytometry (Fig. 1 A). As expected, mRNA expression, as well as protein levels of CD80
and CD83, increased in DCs matured with the FcγRIIB
blocking antibody and in cytokine-matured DCs compared
with isotype-treated IDCs. Of the 24,296 expressed genes
on the array, 1,801 were differentially regulated in DCs
treated with anti-FcγRIIB antibody (RIIB DCs) versus
those treated with isotype control antibody (Iso DCs). Most
of these genes were also up-regulated in DCs matured with
infl ammatory cytokines (Cyt DCs), suggesting that these reflected changes in gene expression shared with other DC
maturation stimuli. However, we also identified a distinct set
of 95 genes that were differentially expressed only in RIIB
DCs (Fig. 1 B and Table S1, available at http://www.jem
.org/cgi/content/full/jem.20062545/DC1). Thus, the GEP
of RIIB DCs includes genes shared with Cyt DCs, as well
as a distinct subset of genes specifically overexpressed only
in RIIB DCs.
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Changes in type I IFN-induced genes after treatment
with anti-Fc𝛄RIIB antibody
Interestingly, a majority of the genes expressed selectively in
RIIB DCs were known to be induced by type I IFNs. To better characterize the IFN-responsive genes in DCs, we treated
IDCs (n = 3) with 1,000 U/ml of IFN-α2b and identified 167
genes that were up-regulated by greater than fivefold at 24 h in
IFN-treated DCs compared with untreated DCs (Fig. 1 C and
Table S2, available at http://www.jem.org/cgi/content/full/
jem.20062545/DC1). Indeed, 54 of 95 genes in the RIIB DC–
specific signature were IFN-inducible genes (Table S1). Upregulation of IFN-induced genes by anti-FcγRIIB antibody
was not unique to DCs, but also observed in monocytes treated
with this antibody (Fig. 1 C). The IFN-induced genes in these
cells included several well-known type I IFN response signature
genes, such as IFN-α inducible (IFI) protein 27, myxovirus resistance 1 (Mx1), Mx2, 2′-5′ oligoadenylate synthase, cig5,
GIP3, IFI16, serpin E, IFI44, STAT1, and IRF-7 (Table S1).
To validate the data for expression of IFN-induced genes in the
microarray, the expression of two of these genes (IFI27 and
Mx1) was also analyzed by real-time PCR, which confirmed
the microarray findings (Fig. 1 D). Surprisingly, this increase in
IRGs was not associated with an increase in the levels of any of
the known type I IFNs themselves (IFN-α, -β, -ω, -τ, and including newer members of the family such as IL28A, IL-28B,
and IL-29; Fig. 1 E) and only a modest increase in IFN-γ at the
mRNA and protein level as analyzed in the supernatants using
Luminex (Table I). It is notable that a low level signal for one of
the type I IFN genes (IFN-α17) was detectable by microarray
in DCs treated with isotype control mAb, and consistent with
this, low levels of IFN-α were also detectable in the supernatants by Luminex (Fig. 1 E and Table I). Importantly, however,
treatment with anti-FcγRIIB mAb did not lead to a change in
the expression of any of the type I IFNs when compared with
isotype mAb-treated cells. Therefore, a distinct component of
FcγR-mediated activation of DCs is the strong and rapid activation of IFN-induced genes without a concurrent increase in
the expression of type I IFNs themselves.
Expression of inflammation-associated chemokines
and cytokines in Fc𝛄R-matured DCs
In addition to the IFN-inducible genes, several other genes
involved in inflammation were also differentially up-regulated
in RIIB DCs relative to Iso DCs or Cyt DCs. This included
several CC chemokines (CCL2/MCP-1, CCL19, CCL3,
CCL5/Rantes, and CCL4/MIP1β), cytokines (IL-1α), FcR,
and complement-related genes. To validate the microarray
data at the protein level, the DC culture supernatants were
also analyzed for the presence of cytokines and chemokines
by Luminex analysis. When compared with Iso DCs, RIIB
DCs secreted greater amounts of MIP1α, IL1α, IL1β, IP10,
IL-12p70, and CCL5/Rantes, which were also consistent with
the microarray data (Table I and Fig. 2). Therefore, DC maturation by selective signaling via activating FcγRs is characterized
by a distinct pattern of inflammation-associated genes relative
to DCs matured using inflammatory cytokines.
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IFN signaling in myeloid cells, particularly DCs, may have a
major impact on immunity to tumors and pathogens, as well
as autoimmunity. An important aspect of the biology of IFN
signaling is that the level of constitutive signaling in the absence of pathogens determines the strength of IFN signaling
in response to pathogens (14). Therefore, there is a need to
identify the factors that regulate the level of this constitutive
or basal IFN signaling.
We show that FcγR-mediated maturation of human DCs
is associated with a distinct pattern of gene expression. This
includes the expression of several inflammation-associated
cytokines and chemokines, and the induction of several typical IRGs. These data suggest that the balance of activating/
inhibitory FcγRs can regulate the IFN response program in
human DCs and monocytes.
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Table I. Expression of cytokines and chemokines secreted by DCs by Luminex analysis
Iso DC
57.19 (29.4)
11 (15.6)
10.2 (4.1)
102.2 (16.2)
0 (0)
229.6 (142.6)
0.1 (0.2)
628.1 (408.1)
22.5 (2.8)
40.5 (28.4)
15.9 (16.6)
8.9 (3.4)
3.8 (7.7)
116.5 (8.8)
5.3 (6.3)
15.5 (19.2)
1173.1 (1074)
27.8 (16.5)
710.6 (351.3)
395.3 (185.4)
10.2 (9.9)

RIIB DC versus Iso DC
(p-value)

RIIB DC versus Cyt DC
(p-value)

699.5 (184.4)
668.9 (780)
14.3 (4.7)
176 (56.5)
0.0
7941.8 (4116.4)
27 (3.8)
10000 (0)
1200.9 (987.5)
4713.3 (5019.4)
148.2 (148.5)
28.9 (21.1)
0.9 (1.8)
264.2 (61.1)
1059.8 (911.3)
35 (11)
2776.34 (2655.6)
1531 (682)
9746.9 (388)
8629.8 (2364.7)
10.3 (12.5)

87.6 (80.8)
NE
21.9 (14)
137.6 (35.5)
0 (0)
NE
16.4 (12.7)
5727 (4992.1)
108.6 (111.5)
3191 (4483.3)
29 (20.1)
39.7 (47.2)
0 (0)
198.3 (81.6)
NE
43.1 (14.5)
1314.8 (1908.4)
264.8 (356.3)
3067.8 (2733.7)
637.9 (664.9)
28.9 (15.6)

<0.001
0.071
0.120
0.023
0.000
0.005
0.000
<0.001
0.027
0.056
0.064
0.055
0.242
0.002
0.030
0.065
0.153
0.002
<0.001
<0.001
0.493

<0.001
NE
0.170
0.147
0.000
NE
0.080
0.069
0.035
0.333
0.082
0.345
0.178
0.122
NE
0.204
0.203
0.008
0.001
<0.001
0.056

IDCs (n = 4) were treated with anti-FcγRIIB antibody (RIIB DC), inflammatory cytokine cocktail (Cyt DC), or isotype control antibody (Iso DC). 24 h later, the
culture supernatant was collected and examined for cytokines and chemokines by Luminex assay. NE, not evaluable, as these cytokines were added exogenously
to Cyt DCs.

Mechanism of Fc𝛄R-mediated induction of type 1
IFN response
Because of the prominence of the IFN signature in RIIB
DCs, we focused on further characterizing the mechanism
for induction of these responses. Type 1 IFN-mediated activation of its receptor activates Jak protein tyrosine kinases,
which in turn phosphorylate STAT proteins, including
STAT1 (16). Therefore, we used the detection of phosphorylated STAT1 (P-STAT1) protein by flow cytometry as a
marker for IFN-induced response at a single-cell level. Treatment of IDCs with the anti-FcγRIIB was associated with an
increase in P-STAT1 detectable at 24 h after anti-FcγRIIB
mAb treatment (Fig. 3 A). The increase in P-STAT1 observed
in these experiments was also confirmed by Western blot
analysis (Fig. 3 B). Anti-FcγRIIB–mediated up-regulation of
P-STAT1 was not unique to DCs, but was also seen in monocytes (Fig. 3 A). In prior studies, we have shown that DC
maturation induced by anti-FcγRIIB requires the presence
of activating Ig ligands in normal human plasma (2). Consistent with this, anti-FcγRIIB enhanced P-STAT1 in DCs
cultured in 1% plasma, but not those cultured in serum-free
media (Fig. 3 C).
Next, we studied the effects of IFN-α blockade on antiFcγRIIB–mediated STAT1 phosphorylation. As expected, the
addition of IFN-α to IDCs led to an increase in P-STAT1,
which was blocked by preincubation of DCs with IFN-α
JEM VOL. 204, June 11, 2007

and IFN-α receptor (IFNAR) blocking antibodies (Fig. 4 A).
However, preincubation with the IFN-α and IFNAR blocking antibodies did not abrogate the up-regulation of P-STAT1
in anti-FcγRIIB–treated DCs (Fig. 4 B). It is notable, however,
that although these mAbs inhibit the increase in P-STAT1 in
response to exogenous IFN-α, they do not abolish the constitutive levels of P-STAT1 (Fig. 4 A and not depicted). Similarly,
pretreatment of monocytes with anti-IFNAR mAb inhibited
the increase in P-STAT1 in response to exogenous IFN-α, but
not after treatment with anti-FcγRIIB (Fig. 4 C).
As there was a mild, but detectable, increase in IFN-γ
in the DC supernatants, we also analyzed the effect of an
IFNγ blocking mAb on anti-FcγRIIB–induced P-STAT1.
The IFNγ blocking antibody was also unable to inhibit the
up-regulation of P-STAT1 in anti-FcγRIIB–treated DCs
(Fig. 4 D). Similar findings were observed in monocytes
(unpublished data). Anti-FcγRIIB–mediated P-STAT1 upregulation was rapid and detectable within an hour of mAb
treatment in both monocytes and DCs (Fig. 4 E). Together,
these data suggest that selective engagement of activating FcγRs
leads to rapid activation of IFN signaling without a concurrent increase in the expression of type I IFNs themselves.
Role of activating Fc𝛄Rs
Induction of DC maturation by anti-FcγRIIB antibody requires the presence of activating Ig ligands present in normal
1361
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IL-1α
IL-1β
IL-2
IL-3
IL-5
IL-6
IL-7
IL-8
IL-10
IL-12p40
IL-12p70
IL-13
IL-15
IFN-γ
TNF-α
Eotaxin
MCP1
Rantes
MIP1a
IP10
IFN-α

Cyt DC

RIIB DC
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differentially expressed between the three groups using a parametric test
with variance assumed equal (ANOVA) with a p-value cut off of 0.05, followed
by the Benjamin and Hochberg false discovery rate multiple correction.
4,759 genes were found to be differentially expressed between Iso DC,
RIIB DC, and Cyt DC. Of these 4,759 genes, 1,801 genes were found to be
differentially expressed in RIIB DCs compared with Iso DCs (twofold
difference; P < 0.05). (left) The expression of these 1,801 genes in RIIB DC
and Iso DC. (right) The expression of the same 1,801 genes in DCs treated
with inflammatory cytokines (Cyt DC). The box shows a subset of 95 genes
that are overexpressed only in RIIB DCs compared with both Iso DCs and
Cyt DCs. Details of these genes are noted in Table S1. (C) Heat map of
IRGs in monocytes and DCs treated with anti-FcγRIIB antibody or isotype
control antibody. Day 5 monocyte derived IDCs (n = 3) were treated with
IFN-α2b (1,000 U/ml) or left untreated. 24 h later, RNA was extracted and
analyzed using the Human Genome U133 Plus2 Affymetrix chips and the
GeneSpring software (version 7.2). 167 genes were found to be upregulated by more than fivefold in IFN-treated DCs compared with untreated
DCs. (left) Expression of the 167 IFN-α–induced genes in DCs treated with
IFN-α and untreated DCs (No Rx). Expression of the 167 IRGs was then
compared in DCs (n = 5) and monocytes (n = 3) treated with antiFcγRIIB mAb (RIIB) or isotype control antibody (Iso). (D) Expression of two
FCγ RECEPTORS ENHANCE INTERFERON SIGNALING | Dhodapkar et al.
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Figure 1. Changes in GEPs of human DCs treated for 24 h with
isotype control antibody, anti-Fc𝛄RIIB antibody, or an inflammatory
cytokine cocktail. (A) Validation of microarray. Immature monocyte–
derived DCs from healthy donors (n = 4) were treated with 20 μg/ml
mouse IgG1 (Iso), 20 μg/ml anti-FcγRIIB blocking antibody (RIIB), or inflammatory cytokine cocktail (IL-1β, TNF-β, PGE2, and IL-6; Cyt). 24 h
later, some DCs from each of the three conditions were analyzed for the
expression of DC maturation markers (CD83 and CD80) by flow cytometry.
RNA was extracted from the rest of the DCs and gene expression was
examined using Human Genome U133 Plus 2 Affymetrix chips. These
graphs show the changes in the expression of DC maturation markers
(CD80 and CD83) at the level of mRNA (by microarray) and protein
(by flow cytometry). (B) Heatmap of 1,801 genes differentially expressed
between Iso DC and RIIB DC. Day 5 immature Mo-DCs were treated with
either 20 μg/ml mouse IgG1 (Iso DC), 20 μg/ml anti-FcγRIIB antibody
(RIIB DC), or inflammatory cytokine cocktail (IL-1β, TNF-β, PGE2, and IL-6;
Cyt DC). 24 h later, the DCs were harvested and RNA was extracted and
analyzed using the Human Genome U133 Plus 2 Affymetrix gene array
chips and the GeneSpring software. Genes that were marked as present
and expressed above a raw level of 100 were included in the analysis.
Iso DC, RIIB DC, and Cyt DC were analyzed to detect genes that were
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human plasma (2). The Mo-DCs used in these experiments
were generated from CD14+ monocytes purified using
immunomagnetic beads and cultured in 1% plasma. These
DCs express higher levels of CD32, as well as CD16, compared with DCs generated from plastic adherent monocytes
(Fig. 5 A and not depicted) (17).To evaluate the role of specific
activating FcγRs, the DCs were preincubated with antibodies
against CD16 and CD32A before blockade of CD32B. Prior
incubation with a cocktail of antibodies against activating
FcγRs, FcγRIIA (CD32A), and FcγRIIIA (CD16) inhibited
anti-FcγRIIB–mediated up-regulation of DC maturation
markers (CD80 and CD83; Fig. 5 B).
Preincubation of DCs with a cocktail of antibodies against
both activating FcγRs (CD32a and CD16) inhibited antiFcγRIIB–mediated induction of P-STAT1 (Fig. 5 C). These
antibodies also blocked anti-FcγRIIB–mediated up-regulation
of STAT1 in monocytes (Fig. 5 D). This was also associated

IFN-induced genes (Mx1 and IFI27) in DCs treated with anti-FcγRIIB mAb
or isotype control was analyzed by TaqMan, and expression data was
compared with the data obtained by microarray analysis. RNA from two
donors (used in the microarray analysis) was analyzed by TaqMan to verify the expression of two IFN-induced genes (Mx1 and IFI27). The figure
shows the Taqman expression data compared with the expression data
JEM VOL. 204, June 11, 2007

Figure 3. Mechanism of Fc𝛄R-mediated induction of IFN response.
(A) Up-regulation of P-STAT1 in DCs or monocytes treated with antiFcγRIIB mAb versus isotype control. Immature Mo-DCs (n = 8) or freshly
isolated monocytes (n = 7) were treated with anti-FcγRIIB antibody (RIIB)
or isotype control antibody (Iso). 24 h later, P-STAT1 expression was examined by flow cytometry. The histogram shows fold change in expression of
P-STAT1 in anti-FcγRIIB antibody–treated versus isotype control antibody–
treated cells. *, P < 0.05. (B) Western blot confirmation of up-regulation
of phosphorylated STAT1 in DCs treated with anti-FcγRIIB antibody
versus isotype control antibody. Monocyte-derived IDCs were treated with
isotype control mouse IgG1 antibody (Iso) or anti-FcγRIIB antibody (RIIB).
24 h later, the DCs were harvested and the protein was analyzed on a
7.5% polyacrylamide gel to detect the presence of phosphorylated STAT1.
(left) Representative of four separate experiments. (right) The summary of
data for quantitative densitometry. Value for P-STAT1 was first normalized
against data for α-tubulin in that sample, before comparison between
RIIB DCs and Iso DCs. Data shown are the summary of four separate
experiments. *, P < 0.05. (C) Expression of phosphorylated STAT1 (P-STAT1)
in DCs treated with anti-FcγRIIB antibody or isotype control antibody in
serum-free medium compared with 1% plasma. Immature monocyte–
derived DCs were treated with anti-FcγRIIB antibody (RIIB DC) or isotype
control antibody (Iso DC) in serum-free medium or in medium supplemented with 1% human plasma. 24 h later, the expression of P-STAT1
was examined by flow cytometry. Data are representative of three similar
experiments. Data represent the mean ± the SD.

with down-regulation of the IFN-induced genes on microarray analysis (unpublished data). To examine the relative
contribution of specific activating FcγRs in anti-FcγRIIB

obtained by microarray analysis. (E) Expression of type I IFNs by microarray. Gene expression data obtained from DCs treated with either isotype
antibody or anti-FcγRIIB antibody, as in Fig. 1 B, was analyzed for the
expression of type I IFN genes. The histogram shows the mean ± the SD
for the mRNA expression from four different donors. Table S1 is available
at http://www.jem.org/cgi/content/full/jem.20062545/DC1.
1363
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Figure 2. Up-regulation of chemokines/cytokines in Fc𝛄R-matured
DCs. Validation of microarray data at the protein level. Monocyte-derived
IDCs (four different donors) were treated with 20 μg/ml anti-FcγRIIB
antibody (RIIB DC) or 20 μg/ml isotype control antibody (mouse IgG1; Iso
DC). 24 h later, DCs were harvested and RNA was extracted and analyzed
using the U133 Plus2 Affymetrix chips (as in Fig. 1). The culture supernatant was analyzed for the expression of cytokines/chemokines by Luminex
analysis. The graphs show the fold increase in mRNA expression (A)
or protein secretion (B) for the cytokines and chemokines in RIIB DC
compared with Iso DC.

Figure 4. Induction of IFN response by anti-Fc𝛄RIIB antibody is
not inhibited by blocking antibodies against IFN-𝛂 and IFN-𝛄. (A) Upregulation of P-STAT1 by exogenous IFN-α is blocked by antibodies
against IFN-α. Monocyte-derived IDCs were either left untreated (DC−)
or treated with IFN-α2b (1,000 U/ml intron A). The DCs were either
treated with a combination of blocking antibodies against IFN-α, as well
as IFNAR (αIFNAR; both at 10 μg/ml) or with their isotype control antibodies (Isotype; mouse IgG1 and mouse IgG2a, respectively; both at
10 μg/ml) for 45 min before treatment with IFN-α. The DCs were analyzed
for their expression of P-STAT1 by flow cytometry. Gray area of the histogram shows staining of the DCs with isotype control (Mouse IgG2a) for
P-STAT1 antibody. The graph represents one of two similar experiments.
(B) Effect of blocking antibodies against IFN-α on anti-FcγRIIB–mediated
induction of P-STAT1. Monocyte-derived IDCs were treated with antiFcγRIIB antibody (5 μg/ml RIIB) or mouse IgG1 isotype control antibody (Iso). DCs treated with anti-FcγRIIB antibody were either treated
with blocking antibodies against IFN-α and IFNAR (10 μg/ml RIIB +
αIFNa+αIFNAR) or isotype control antibody (RIIB + Isotype; 10 μg/ml
mouse IgG2a and 10 μg/ml IgG1, respectively) for 45 min before the
addition of anti-FcγRIIB antibody. 24 h later, flow cytometry was performed
to examine the expression of P-STAT1. Some DCs were also stained with
mouse IgG2a, which is isotype control for the P-STAT1 antibody. One of
two similar experiments. (C) Effect of anti-IFNAR blocking antibody on
anti-FcγRIIB–mediated induction of P-STAT1. Freshly isolated PBMCs
were treated with IFN-α2b (1,000 U/ml intron A) or anti-FcγRIIB antibody
and an isotype control antibody either in the presence of 20 μg/ml IFNAR
antibody (IFNAR Ab) or isotype control antibody (mouse IgG2a). 1 h later,
flow cytometry was performed to examine the expression of P-STAT1 on
CD14+ monocytes. Data shown are the summary of three similar experiments. *, P < 0.05. Data represent the mean ± the SD. (D) IFNγ blocking
antibodies do not inhibit the up-regulation of P-STAT1 by anti-FcγRIIB
antibody. IDCs were treated with either anti-FcγRIIB antibody (5 μg/ml
RIIB) or isotype control antibody (Iso). DCs treated with anti-FcγRIIB antibody were either treated with blocking antibodies against IFNγ and IFNAR
(10 μg/ml RIIB + αIFNγ) or isotype control antibody (10 μg/ml RIIB + Isotype; mouse IgG1) for 45 min before the addition of anti-FcγRIIB antibody.
24 h later, flow cytometry was performed to examine the expression of
1364

Role of STAT1 in Fc𝛄R-mediated DC maturation
Prior studies have shown that type I IFNs can mediate phenotypic and functional activation of human DCs. We hypothesized that the activation of IFN pathway/STAT1 by
anti-FcγRIIB mAb may be essential for FcγR-mediated DC
maturation. To test this directly, we knocked down STAT1
protein in IDCs using RNAi. IDCs were electroporated with
STAT1 siRNA or nontargeted control siRNA. The expression of STAT1 protein was markedly inhibited at 48 and 72 h
in DCs treated with STAT1 siRNA, but not in nontargeted
control siRNA (Fig. 6 A). At 72 h after treatment with
siRNA, DCs were treated with anti-FcγRIIB or isotype
control mAb. DCs treated with STAT1 siRNA showed
decreased up-regulation of maturation markers (CD80 and
CD83; Fig. 6, B and C). However, these DCs were capable
of maturation in response to an inflammatory cytokines cocktail. Therefore, STAT1 plays an important role in FcγRmediated induction of DC maturation.
DISCUSSION
ICs and antibodies play an important role in autoimmune
and allergic inflammation and in protection from infectious
pathogens (21). The immunologic effects of ICs depend on
the balance between activating and inhibitory FcγRs, including in DCs (3, 21). These data demonstrate that manipulating
this balance via antibody-mediated blockade of inhibitory
FcγRIIB in the presence of activating ligands in the human

P-STAT1. Some DCs were also stained with mouse IgG2a, which is
isotype control for the P-STAT1 antibody. The graph shows one of two
similar experiments. (E) Anti-FcγRIIB induced up-regulation of P-STAT1
is rapid. Immature monocyte derived DCs (left) or monocytes (right) were
treated with 10 μg/ml anti-FcγRIIB antibody (RIIB) or mouse IgG1 isotype
control antibody (Iso). 1 h later flow cytometry was performed to detect
the expression of P-STAT1. Gray histogram shows staining with mouse
IgG2a isotype control antibody for P-STAT1. The graphs show one of five
similar experiments.
FCγ RECEPTORS ENHANCE INTERFERON SIGNALING | Dhodapkar et al.
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mAb-mediated STAT1 up-regulation, we also evaluated the
effect of individual blockade of FcγRIIIA and FcγRIIA on upregulation of P-STAT1. Blockade of FcγRIIIA on monocytes with clone 3G8 led to greater inhibition of P-STAT1
up-regulation, compared with FcγRIIA blocking antibody
(clone IV.3), suggesting that FcγRIIIA may be the major activating FcγR contributing to STAT1 phosphorylation in
monocytes (Fig. 5 E). Aggregation of FcγRs bearing ITAM
motifs leads to the activation of Syk family of tyrosine kinases
(18, 19). Tassiulas et al. recently demonstrated that Syk and
associated adaptor proteins can enhance IFN-α signaling by
direct phosphorylation of STAT1 (20). Consistent with this,
pretreatment of DCs with a Syk inhibitor, piceatannol, inhibited
the up-regulation of P-STAT1, as well as maturation induced
by anti-FcγRIIB (Fig. 5 F). Collectively, these data suggest that
the signals via activating FcγRs contribute to the induction of
P-STAT1 under these experimental conditions.

ARTICLE

JEM VOL. 204, June 11, 2007

with blocking antibody to CD16 (3G8), CD32A (IV.3), or a combination of
blocking antibodies against CD16 and CD32A (3G8 + IV.3) or their isotype control antibodies (mouse IgG1 and mouse IgG2a, respectively; Iso). 1 h
later, the expression of P-STAT1 in CD14+ monocytes was analyzed by
flow cytometry. The change in expression of P-STAT1 between MIgG1treated cells and anti-FcγRIIB–treated cells was considered as 100%. The
figure shows the percentage of decrease in this P-STAT1 phosphorylation
by blocking antibodies against CD16 (αCD16) and CD32A (αCD32A),
either alone or in combination (αCD16 + αCD32A). The histogram shows
the summary of experiments on three separate donors (*, P < 0.05).
(F) Inhibition of Syk tyrosine kinase abrogates anti-FcγRIIB induced upregulation of P-STAT1. Immature Mo-DCs were treated with medium alone
(medium) or Syk tyrosine kinase inhibitor piceatannol (PICE) at 5 μmol
concentration. 30 min later, the DCs were treated with either anti-FcγRIIB
antibody or isotype control mouse IgG1 antibody (MIgG1). 24 h later, the
DCs were analyzed for their P-STAT1 expression and maturation (CD80
and CD83) by flow cytometry. Change in expression of P-STAT1, as well as
maturation between MIgG1-treated cells and anti-FcγRIIB–treated cells,
was considered as 100%. The histogram on the left shows the percentage
of decrease in this P-STAT1 phosphorylation by piceatannol treatment.
The histogram on the right shows the percentage of decrease in DC
maturation by piceatannol treatment. The graphs are a summary
of experiments on three separate donors (*, P < 0.05). Data represent
the mean ± the SD.
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Figure 5. Role of activating Fc𝛄Rs in the FcR-mediated DC maturation and induction of P-STAT1. (A) Expression of FcγRI, RIIA, RIIB,
and RIIIA on DCs generated from CD14+ monocytes by flow cytometry.
Day 5 monocyte-derived IDCs were examined for the expression of FcγR1,
FcγRIIA, FcγRIIB, and FcγRIII by flow cytometry. The area in gray represents staining with isotype control antibodies. Figure represents one of six
similar experiments. (B) Down-regulation of anti-FcγRIIB antibody induced DC maturation by blocking antibodies against activating FcγR. IDCs
(n = 4) were treated with isotype control antibody or anti-FcγRIIB antibody either with blocking antibodies against CD32A and CD16 antibody
(αCD32A + αCD16; clone IV.3 and 3G8, both at 10 μg/ml) or their
isotype control antibodies (Isotype; mouse IgG2a and IgG1, respectively).
24 h later, the expression of CD80 and CD83 was monitored by flow cytometry, and the double-positive cells were used to assess DC maturation.
Change in maturation between isotype-treated and anti-FcγRIIB–treated
DCs was considered as 100%. The figure shows the percentage of
decrease in maturation of DCs treated with blocking antibodies against
the activating FcγR (CD32A and CD16). Data are a summary of four similar
experiments. *, P < 0.05. (C and D) Down-regulation of anti-FcγRIIB antibody induced P-STAT1 by blocking antibodies against activating FcγRs.
IDCs (C) or PBMCs (D) were treated with mouse IgG1 isotype control antibody (Isotype) or anti-FcγRIIB antibody (RIIB). Some of the DCs and
PBMCs treated with anti-FcγRIIB antibody were pretreated with blocking
antibodies against CD32A and CD16 (αCD32A + αCD16; clone IV.3 and
clone 3G8, respectively, both 10 μg/ml) or isotype control antibodies for
the CD32A and CD16 blocking antibodies (mouse IgG2a and mouse IgG1,
respectively; 10 μg/ml) for 45 min. Expression of P-STAT1 on CD11c+ DCs
or CD14+ monocytes was examined by flow cytometry. Data are representative of four similar experiments for DCs and three for monocytes.
(E) PBMCs were treated with MIgG1 isotype control antibody or antiFcγRIIB antibody. Some of the anti-FcγRIIB–treated PBMCs were pretreated

serum has major effects on gene expression and activation
status of human monocytes and DCs. Signaling via activating
FcγRs on DCs provides a distinct form of maturation stimulus that is characterized by the expression of P-STAT1 and
several IRGs, as well as inflammation-associated chemokines/
cytokines. Activation of P-STAT1 is critical to FcγR-mediated
effects on DCs, because suppression of STAT1 inhibits FcγRmediated DC maturation.
The finding that FcγR signaling can alter the expression
of IRGs has implications for the regulation of IFN signaling
in FcγR-expressing myeloid cells. Typically, induction of
IFNs in response to viral pathogens is mediated by cytosolic receptors (e.g., RIG1 and MDA5) in infected cells,
or endosomal receptors (e.g., Toll receptor family) in antigenpresenting cells (22). Downstream signaling in response to IFNs
and activation of Jak–STAT pathway is also highly regulated
(e.g., by the PIAS or SOCS family of proteins) (23). However, studies by Taniguchi et al. have shown that the strength
of IFN response to pathogens depends on the level of constitutive signaling in the absence of pathogens (14). Our data
suggest that the balance of activating/inhibitory FcγR signaling in DCs may have a direct impact on this basal level of
IFN signaling in myeloid cells in the absence of pathogens.
This balance may, in principle, be altered both in the context
of specific FcγR polymorphisms, or the ability of ICs to bind
activating versus inhibitory FcγRs.
Aggregation of FcγRs bearing ITAM motifs leads to the
activation of Syk family of tyrosine kinases (18, 19). Tassiulas
et al. recently showed that Syk and associated adaptor proteins can enhance IFN-α signaling by direct phosphorylation
of STAT1 (20). Our data extend these observations and suggest a role for activating FcγRs on human monocytes and

DCs in enhancing the expression of IRGs. Further studies are
needed to evaluate this pathway.
Importantly, the FcγR-mediated induction of IRGs was
not associated with a detectable increase in the expression of
any of the type I IFNs, and it did not require the addition of
exogenous IFNs to these cultures. Blocking mAbs against
IFNAR and IFN-α, which block the increase in P-STAT in
response to exogenous IFN-α, also fail to block this response.
The induction of STAT1 phosphorylation by anti-FcγRIIB
was rapid and detectable within 1 h of treatment with anti1366
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Figure 6. Fc𝛄R-mediated DC maturation can be inhibited by
STAT1 knockdown. (A) Day 4 IDCs were electroporated with 10 μg
of STAT1 siRNA (STAT1) or nontargeting siRNA (Control). Some DCs were
cultured without electroporation (No electr). The DCs were harvested
48 and 72 h after electroporation, and a Western blot was performed to
detect total STAT1 protein. Data are representative of two separate experiments. (B and C) DCs were harvested 72 h after electroporation with
either STAT1 siRNA or nontargeting control siRNA. Some nonelectroporated DCs were also harvested. The DCs were treated with anti-FcγRIIB
antibody or isotype control antibody. Some of the DCs electroporated with
STAT1 siRNA were also treated with the inflammatory cytokine cocktail.
24 h later, DC maturation was determined by examining the expression
of CD80, CD83, and CD11c by flow cytometry. (B) Summary of data
in four independent experiments (mean ± the SD; *, P < 0.05). (C) Data
from a representative experiment.

FcγRIIB blocking antibodies, which also argues against the
IFN signature being caused by synthesis of new IFNs. It is
also important to emphasize that the IFN signature is not
observed in DCs treated specifically with inflammatory cytokines (Cyt DCs). Collectively, these data suggest a novel link
between FcγR signaling and IFN response in human DCs
and monocytes. However, it is important to note that low
levels of type I IFNs (IFN-α17) were expressed in control
DCs and detectable in supernatants (although unchanged in
response to anti-FcγRIIB mAb). Furthermore, the IFNAR
blocking antibodies were unable to block the constitutive
level of P-STAT1. Therefore, the observed effects are consistent with the ability of FcγR-mediated signals to modify the
constitutive IFN signaling in these cells (14).
The nature of specific activating FcγRs and other signals
that are important for regulating IFN signaling in DCs requires further study and may be cell/tissue type specific. In
our experiments, the signal was delivered via both FcγRIIIA
and FcγRIIA. Recent studies have shown that FcγRIIIA is
expressed on distinct subsets of human monocytes and DCs
(24, 25), although their functional significance remains to be
clarified. Polymorphisms in both FcγRIIA and FCγRIIIA
may therefore have a significant impact on immune activation
mediated by ICs and antibody-coated tumor cells (26, 27).
Selective blockade of inhibitory FcγR signaling on DCs
also leads to the up-regulation of several other genes not in
the type I IFN pathway, but implicated in autoimmune and
allergic inflammation. These include several CC chemokines,
such as CCL5, CCL4, and CCL3, which were documented
at both mRNA and protein level. Expression of these chemokines may allow FcγR-matured DCs to attract several immune cells, including T cells, monocytes, DCs, and eosinophils,
which play an important role in inflammation (28).
These data also have several clinical implications. Dysregulation of FcγR signaling may contribute to the altered
IFN signaling observed in several autoimmune states (13, 27).
Therefore, either restoring the FcγR balance or inhibiting
STAT1 may help suppress immune activation in lupus. Indeed, recent studies have shown that only small changes in
inhibitory FcγR can have major effects on immunopathology
in lupus (29). Altered IFN signaling and STAT1/STAT3 ratio
in myeloid DCs and other myeloid cells has also been implicated in the loss of protective antitumor immunity and immune surveillance in several models (12, 30, 31). Interestingly,
recent studies have also implicated a more direct role for ICs
in promoting tumor growth (32). Our observations may serve
to link these findings together. Manipulating FcγR balance
on tumor-infiltrating DCs (e.g., via anti-FcγRIIB antibodies)
may be of value as a general approach to regulate endogenous
antitumor immunity. Modulation of IFN signaling may also
contribute to the efficient induction of T cell immunity observed by selectively targeting ICs or antibody-coated tumor
cells to activating FcγRs on human and murine DCs (2, 3,
33, 34); therefore, manipulating the FcγR balance may also
be targeted for improving the efficacy of antibody-based
therapy (35) or DC-based immunotherapy of cancer (36).
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MATERIALS AND METHODS

Microarray analysis. IDCs on day 5 of culture (n = 5) or CD14+ monocytes isolated from immunomagnetic bead selection (n = 3) were treated
with 20 μg/ml anti-FcγRIIB mAb, isotype control (mouse IgG1 mAb), or
inflammatory cytokine cocktail. After 24 h of culture, cells were pelleted in
RLT buffer. RNA was extracted from the DCs using the RNeasy kit (QIAGEN)
as per the manufactures protocol. Total RNA (1–2 μg) was labeled and hybridized using the Enzo T7 labeling kit (Life Sciences) on Affymetrix Human
Genome U133 Plus 2.0 microarray (Affymetrix). Washing and scanning was
done with Fluidics Station 400 and GeneChip Scanner 3000 (both from Affymetrix) following the manufacturer’s protocol. Affymetrix GCOS 1.2 software was used to obtain the raw signal and present/absent gene data. Further
analysis of the data was performed using GeneSpring software version 7.2
(Silicon Genetics).
Data analysis of microarray data. The methodology for analysis of
microarray data was similar to that used by Napolitani et al. (38). The microarray data was normalized as follows. The signal values below 0.01 were set to
0.01. The percentile for all the measurements in each sample was calculated
using the values for all genes not marked “absent.” Each measurement was
divided by the 50th percentile of all measurements in that sample. Each gene
was divided by the median of its measurements in all samples. Genes that
were marked as present and expressed a raw level of >100 were included in
the analysis. 29,499 genes passed this filter. Gene expressions in DCs treated
with inflammatory cytokines, FcγRIIB blocking antibody, and isotype control antibody were compared, and genes with statistically different expression
between the groups based on the values of the replicates were calculated using a parametric test with variance assumed equal (ANOVA) using a p-value
cut off of 0.05, followed by Benjamin and Hochberg false discovery rate
multiple-test correction. A gene list of 4,759 significant genes was obtained
and used to determine fold changes in expression between the three different
conditions. Of these 4,759 genes, 1,801 genes were differentially regulated
between FcγRIIB antibody-treated DCs by twofold or higher, compared
with isotype control antibody–treated DCs. Microarray data are available
in the National Center for Biotechnology Information Gene Expression
Omnibus (http://www.ncbi.nih.gov/geo/) under accession no. GSE7509.
Real time PCR (TaqMan) analysis. RNA was isolated with RNeasy
Mini kit (Qiagen) and RT-PCR was conducted with Assays-on-Demand
primer-probe for IFI27 and Mx1 using the ABI PRISM 7700 sequence detection system (both Applied Biosystems). Expression of GAPDH was monitored as a housekeeping gene. Reactions were set up in triplicates using
EZ PCR Core Reagents (Applied Biosystems) according to the manufacturer’s
instructions with 20 ng of total RNA. Relative expression of target genes
was calculated using the comparative threshold cycle method.
JEM VOL. 204, June 11, 2007

Luminex assay. Cell supernatants from 24-h DC cultures were analyzed
for 20 cytokines and chemokines using the Protein Multiplex Immunoassay
kit (Biosource International) as per the manufacturer’s protocol. In brief,
Multiplex beads (Biosource) were vortexed and sonicated for 30 s, and 25 μl
was added to each well and washed two times with wash buffer. The samples
were diluted 1:2 with assay diluent and loaded onto a Multiscreen BV 96well filter plate (Millipore) with 50 μl of incubation buffer already added to
each well. Serial dilutions of cytokine standards were prepared in parallel and
added to the plate. Samples were then incubated on a plate shaker at 600 rpm
in the dark at room temperature for 2 h. The plate was applied to a Multiscreen Vacuum Manifold (Millipore) and washed twice with 200 μl of wash
buffer. 100 μl of biotinylated anti–human Multi-Cytokine Reporter (Biosource International) was added to each well. The plate was incubated on a
plate shaker at 600 rpm in the dark at room temperature for 1 h. The plate
was applied to a Multiscreen Vacuum Manifold (Millipore) and washed
twice with 200 μl of wash buffer. Streptavidin-phycoerythrin was diluted
1:10 in wash buffer, and 100 μl was added directly to each well. The plate
was incubated on a plate shaker at 600 rpm in the dark at room temperature
for 30 min. The plate was then applied to the vacuum manifold, washed
twice, and each well was resuspended in 100 μl wash buffer and shaken for
1 min. The assay plate was then transferred to the Bio-Plex Luminex 100
XYP instrument (Millipore) for analysis. Cytokine concentrations were calculated using Bio-Plex Manager 3.0 software with a 5-parameter curvefitting algorithm applied for standard curve calculations.
Detection of STAT1 phosphorylation by flow cytometry. The methodology for the detection of P-STAT1 by flow cytometry was adapted from
that described by Lesinski et al. (39). Freshly isolated PBMCs, purified
CD14+ monocytes, or monocyte-derived IDCs were treated with either
mouse IgG1 isotype control antibody or the FcγRIIB blocking antibody.
After a 1–24-h culture, the cells were labeled with the mouse anti–human
phospho STAT1 antibody (clone pY701; BD Biosciences) as per the manufacturer’s protocol. In some experiments, cells were treated with 1,000 IU/ml
IFN-α 2b (Schering-Plough). In some experiments, DCs or monocytes
were pretreated with 10 μg/ml anti-IFNAR mAb (Fitzgerald Industries),
10 μg/ml anti-IFN α antibody (clone MMHA-1; PBL Laboratories), 10 μg/ml
anti–IFN-γ antibody (clone MMHG-1; PBL Laboratories), 10 μg/ml antiCD16 (clone 3G8; BD Biosciences), and 10 μg/ml antiCD32A (clone IV.3)
or isotype controls.
Blocking inhibitory Fc𝛄R on human Mo-DCs and evaluation of
their maturation. In brief, IDCs were harvested on day 5 of culture and
treated with either 10 μg/ml anti–human FcγRIIB blocking antibody (clone
2B6) or 10 μg/ml mouse IgG1 isotype control antibody (Sigma-Aldrich).
After overnight culture, DCs were harvested to assess DC maturation. In
some experiments, DCs were pretreated with 10 μg/ml CD16 blocking
antibody (clone 3G8; BD Biosciences), and 10 μg/ml CD32A blocking antibody (clone IV.3) or isotype controls for 1 h before treatment with anti–human
FcγRIIB blocking antibody. The following antibodies were used for evaluating the surface changes associated with DC maturation: CD11c-APC,
CD80-PE, CD83-FITC, CD86-PE, and HLA-DR-FITC (all obtained from
Becton Dickinson).
Inhibition of STAT1 synthesis by RNA interference. CD14+ monocytes were cultured in 1% plasma supplemented with IL4 and GMCSF on
days 0 and 2, as described in Generation of DCs. On day 4, the IDCs were
harvested, washed with Opti-MEM I medium without phenol red (Invitrogen) and resuspended in Opti-MEM I at a concentration of 2.5 × 107 cells/ml.
4 × 106 IDCs were electroporated with 10 μg of STAT1 (siRNA;
siGENOME SMARTpool; Thermo Fisher Scientific) or nontargeting
siRNA (siCONTROL Nontargeted siRNA; Thermo Fisher Scientific) in a
4-mm electroporation cuvette using the ECM830 Square Wave Electroporator (Harvard Apparatus). The pulse conditions were a square wave pulse of
500V and 0.5 ms. The electroporated DCs were immediately resuspended in
complete medium (RPMI 1% plasma) supplemented with IL4 and GMCSF.
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Generation of DCs. PBMCs were isolated from blood of healthy donors
via density gradient centrifugation using Ficoll-Hypaque (GE Healthcare).
CD14+ cells were obtained using CD14 microbeads and LS columns (Miltenyi
Biotec) and used to generate DCs. DCs were generated by culturing CD14+
cells in RPMI-1640 medium with l-glutamine ( Mediatech) supplemented
with 1% single donor plasma, gentamicin (20 μg/ml; BioWittaker), and
0.01 M Hepes (Cambrex). For some experiments, DCs were cultured in
AIM-V serum free medium (Invitrogen). 20 ng/ml GM-CSF (Immunex) and
12.5 ng/ml IL-4 (R&D Systems) were added to the culture on days 0, 2, and 4.
On day 5 of culture, IDCs were either treated with 10–20 μg/ml antiFcγRIIB antibody (clone 2B6; MacroGenics), 10–20 μg/ml mouse IgG1
isotype control (Sigma-Aldrich), or inflammatory cytokine cocktail (10 ng/ml
IL-1β, 1,000 U/ml IL-6, 10 ng/ml TNF-α (all from R&D Systems), and prostaglandin E2 (1 μg/ml, Sigma-Aldrich). As R/H polymorphisms of the activating
receptor CD32A can potentially impact FcR-mediated DC maturation, they
were monitored by flow cytometry using specific antibodies (17, 37). All donors in this study had HH/HR genotype (not depicted). Purity of the DC
preparations was evaluated by flow cytometry and was >95%. The percentage of contaminating NK cells was <0.1%.
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Western blot analysis to detect total and phosphorylated STAT1.
Nonelectroporated DCs, as well as DCs electroporated with either nontargeting RNAi or STAT1 RNAi, were harvested, washed in PBS, and lysed
with the radioimmunoprecipitation assay buffer containing 150 mM NaCL,
10 mM Tris, pH 7.2, 0.1% SDS, 1% Triton X-100, 1% deoxycholate, 5 mM
EDTA, 100 mM sodium orthovanadate, and protease inhibitors (protease
inhibitor cocktail tablet; Boehringer Mannheim). 25–50 μg of protein was
resolved on a 7.5% polyacrylamide gel and transferred to a nitrocellulose
membrane. Blots were probed with total STAT1 antibody (rabbit anti–
human STAT1, 1:1,000; Cell Signaling Technologies) overnight according
to the manufacturers protocol. The membrane was treated with goat anti–
rabbit horseradish peroxidase secondary antibody (1:5,000; Southern Biotechnology). Detection was done using the ECL plus Western blot detection
reagents (GE Healthcare).
For the detection of phosphorylated STAT1 protein, IDCs were treated
with mouse IgG1 isotype control antibody or anti-FcγRIIB antibody. 24 h
later, the cells were harvested and lysed with the radioimmunoprecipitation
assay buffer containing 150 mM NaCL, 10 mM Tris, pH 7.2, 0.1% SDS, 1%
Triton X-100, 1% deoxycholate, 5 mM EDTA, protease inhibitors, 10 mM
sodium orthovanadate, and 10 mM β glycerol phosphate. Protein was resolved on a 7.5% polyacrylamide gel and transferred to a nitrocellulose
membrane. Blots were probed with mAb specific for phosphorylated STAT1
(rabbit anti–human phospho-STAT1 antibody; 1:1,000, Cell Signaling
Technologies) overnight, according to the manufacturers protocol. The
membrane was treated with goat anti–rabbit horseradish peroxidase secondary antibody (1:5,000; Southern Biotechnology). Detection was done using
the ECL plus Western blot detection reagents (GE Healthcare), and analyzed
by quantitative densitometry using ImageJ software (W.S. Rasband, National
Institutes of Health, Bethesda, MD; http://rsb.info.nih.gov/ij/). Data for
P-STAT1 were first normalized against values for α-tubulin in that sample,
before comparison to other samples.

REFERENCES

Detection of DC maturation after STAT1 knockdown with the
STAT1 RNAi. Nonelectroporated DCs or DCs electroporated with either
STAT1 siRNA or nontargeting control siRNA were harvested 72 h after
electroporation. DCs were treated with anti-FcγR antibody or mouse IgG1
isotype control antibody. 24 h later, flow cytometry was performed to examine the surface expression of CD83, CD80, and CD11c.
Online supplemental material. Table S1 shows a list of 95 genes that
are differentially expressed in DCs treated with anti-FcγRIIB antibody.
Table S2 shows a list of genes up-regulated by more than fivefold at 24 h in
immature Mo-DCs cultured in the presence of IFN-α2b (1,000 U/ml),
compared with untreated DCs. The MIAME checklist for microarray analysis
is presented as supplemental text.
The authors thank Drs. Ezio Bonvini and Jeff Stavenhagen for critical review of
the paper, Dr. Virginia Pascual for thoughtful discussions, and Judy Adams for help
with figures.
This work was supported in part by funds from the National Institutes of
Health (AI054375 to K.M. Dhodapkar; CA106802 and CA109465 to M.V. Dhodapkar;
PO1-AI51573 to R.M. Steinman and J.V. Ravetch; and MO1-RR00102 to The
Rockefeller University General Clinical Research Center), the Dana Foundation, the
American Society of Clinical Oncology Career Development award, the Alexandrine
and Alexander Sinsheimer award (to K.M. Dhodapkar), the Damon Runyon Eli Lilly
Clinical Investigator Award (to M.V. Dhodapkar), and the Montreal General Hospital
Foundation (D. Banerjee).
K.M. Dhodapkar, M.V. Dhodapkar, R.M. Steinman, and J.V. Ravetch are
coinventors on a patent application that describes the processes used in this study.
These processes are licensed by The Rockefeller University to Macrogenics, Inc.
M.C. Veri is an employee of Macrogenics, Inc. J.V. Ravetch has a financial interest in
Macrogenics, Inc. which is managed by the Rockefeller University’s conflict of
interest committee. The remaining authors declare no financial conflict of interest.
1368

1. Ravetch, J.V., and S. Bolland. 2001. IgG Fc receptors. Annu. Rev.
Immunol. 19:275–290.
2. Dhodapkar, K.M., J.L. Kaufman, M. Ehlers, D.K. Banerjee, E. Bonvini,
S. Koenig, R.M. Steinman, J.V. Ravetch, and M.V. Dhodapkar. 2005.
Selective blockade of inhibitory Fc gamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibodycoated tumor cells. Proc. Natl. Acad. Sci. USA. 102:2910–2915.
3. Kalergis, A.M., and J.V. Ravetch. 2002. Inducing tumor immunity
through the selective engagement of activating Fc receptors on dendritic
cells. J. Exp. Med. 195:1653–1659.
4. Pestka, S., C.D. Krause, and M.R. Walter. 2004. Interferons, interferonlike cytokines, and their receptors. Immunol. Rev. 202:8–32.
5. Platanias, L.C. 2005. Mechanisms of type-I- and type-II-interferonmediated signalling. Nat. Rev. Immunol. 5:375–386.
6. Theofilopoulos, A.N., R. Baccala, B. Beutler, and D.H. Kono. 2005.
Type I interferons (alpha/beta) in immunity and autoimmunity. Annu.
Rev. Immunol. 23:307–336.
7. Le Bon, A., G. Schiavoni, G. D’Agostino, I. Gresser, F. Belardelli, and
D.F. Tough. 2001. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells
in vivo. Immunity. 14:461–470.
8. Tudor, D., S. Riffault, C. Carrat, F. Lefevre, M. Bernoin, and B.
Charley. 2001. Type I IFN modulates the immune response induced
by DNA vaccination to pseudorabies virus glycoprotein C. Virology.
286:197–205.
9. Van Uden, J.H., C.H. Tran, D.A. Carson, and E. Raz. 2001. Type I
interferon is required to mount an adaptive response to immunostimulatory
DNA. Eur. J. Immunol. 31:3281–3290.
10. Le Bon, A., N. Etchart, C. Rossmann, M. Ashton, S. Hou, D.
Gewert, P. Borrow, and D.F. Tough. 2003. Cross-priming of CD8+
T cells stimulated by virus-induced type I interferon. Nat. Immunol.
4:1009–1015.
11. Gallucci, S., M. Lolkema, and P. Matzinger. 1999. Natural adjuvants:
endogenous activators of dendritic cells. Nat. Med. 5:1249–1255.
12. Dunn, G.P., A.T. Bruce, K.C. Sheehan, V. Shankaran, R. Uppaluri,
J.D. Bui, M.S. Diamond, C.M. Koebel, C. Arthur, J.M. White, and
R.D. Schreiber. 2005. A critical function for type I interferons in cancer
immunoediting. Nat. Immunol. 6:722–729.
13. Blanco, P., A.K. Palucka, M. Gill, V. Pascual, and J. Banchereau. 2001.
Induction of dendritic cell differentiation by IFN-alpha in systemic
lupus erythematosus. Science. 294:1540–1543.
14. Taniguchi, T., and A. Takaoka. 2001. A weak signal for strong responses:
interferon-alpha/beta revisited. Nat. Rev. Mol. Cell Biol. 2:378–386.
15. Jonuleit, H., U. Kuhn, G. Muller, K. Steinbrink, L. Paragnik, E. Schmitt,
J. Knop, and A.H. Enk. 1997. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells
under fetal calf serum-free conditions. Eur. J. Immunol. 27:3135–3142.
16. Darnell, J.E., Jr., I.M. Kerr, and G.R. Stark. 1994. Jak-STAT pathways
and transcriptional activation in response to IFNs and other extracellular
signaling proteins. Science. 264:1415–1421.
17. Boruchov, A.M., G. Heller, M.C. Veri, E. Bonvini, J.V. Ravetch, and
J.W. Young. 2005. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 115:2914–2923.
18. Daeron, M. 1997. Fc receptor biology. Annu. Rev. Immunol.
15:203–234.
19. Sedlik, C., D. Orbach, P. Veron, E. Schweighoffer, F. Colucci, R.
Gamberale, A. Ioan-Facsinay, S. Verbeek, P. Ricciardi-Castagnoli, C.
Bonnerot, et al. 2003. A critical role for Syk protein tyrosine kinase in
Fc receptor-mediated antigen presentation and induction of dendritic
cell maturation. J. Immunol. 170:846–852.
20. Tassiulas, I., X. Hu, H. Ho, Y. Kashyap, P. Paik, Y. Hu, C.A. Lowell,
and L.B. Ivashkiv. 2004. Amplification of IFN-alpha-induced STAT1
activation and inflammatory function by Syk and ITAM-containing
adaptors. Nat. Immunol. 5:1181–1189.
FCγ RECEPTORS ENHANCE INTERFERON SIGNALING | Dhodapkar et al.

Downloaded from http://rupress.org/jem/article-pdf/204/6/1359/1004704/jem_20062545.pdf by Rockefeller University user on 17 August 2020

Inhibition of STAT1 protein was examined by Western blot analysis 2 and
3 d after electroporation.

ARTICLE

JEM VOL. 204, June 11, 2007

31. Ho, H.H., and L.B. Ivashkiv. 2006. Role of STAT3 in type I interferon
responses. Negative regulation of STAT1-dependent inflammatory
gene activation. J. Biol. Chem. 281:14111–14118.
32. Tan, T.T., and L.M. Coussens. 2007. Humoral immunity, inflammation and cancer. Curr. Opin. Immunol. 19:209–216.
33. Regnault, A., D. Lankar,V. Lacabanne, A. Rodriguez, C.Thery, M. Rescigno,
T. Saito, S.Verbeek, C. Bonnerot, P. Ricciardi-Castagnoli, and S. Amigorena.
1999. Fcγ receptor-mediated induction of dendritic cell maturation and
major histocompatibility complex class I-restricted antigen presentation
after immune complex internalization. J. Exp. Med. 189:371–380.
34. Dhodapkar, K.M., J. Krasovsky, B. Williamson, and M.V. Dhodapkar.
2002. Antitumor monoclonal antibodies enhance cross-presentation of
cellular antigens and the generation of myeloma-specific killer T cells by
dendritic cells. J. Exp. Med. 195:125–133.
35. Weiner, L.M., M.V. Dhodapkar, and S. Ferrone. 2007. Monoclonal
antibodies for cancer immunotherapy. Lancet. In press.
36. Dhodapkar, K.M., and M.V. Dhodapkar. 2005. Recruiting dendritic
cells to improve antibody therapy of cancer. Proc. Natl. Acad. Sci. USA.
102:6243–6244.
37. Micklem, K.J., W.P. Stross, A.C. Willis, J.L. Cordell, M. Jones, and
D.Y. Mason. 1990. Different isoforms of human FcRII distinguished by
CDw32 antibodies. J. Immunol. 144:2295–2303.
38. Napolitani, G., A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia.
2005. Selected Toll-like receptor agonist combinations synergistically
trigger a T helper type 1-polarizing program in dendritic cells. Nat.
Immunol. 6:769–776.
39. Lesinski, G.B., S.V. Kondadasula, T. Crespin, L. Shen, K. Kendra, M.
Walker, and W.E. Carson III. 2004. Multiparametric flow cytometric
analysis of inter-patient variation in STAT1 phosphorylation following
interferon Alfa immunotherapy. J. Natl. Cancer Inst. 96:1331–1342.

1369

Downloaded from http://rupress.org/jem/article-pdf/204/6/1359/1004704/jem_20062545.pdf by Rockefeller University user on 17 August 2020

21. Ravetch, J.V. 2002. A full complement of receptors in immune complex diseases. J. Clin. Invest. 110:1759–1761.
22. Stetson, D.B., and R. Medzhitov. 2006. Type I interferons in host
defense. Immunity. 25:373–381.
23. van Boxel-Dezaire, A.H., M.R. Rani, and G.R. Stark. 2006. Complex
modulation of cell type-specific signaling in response to type I interferons.
Immunity. 25:361–372.
24. Geissmann, F., S. Jung, and D.R. Littman. 2003. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity.
19:71–82.
25. MacDonald, K.P., D.J. Munster, G.J. Clark, A. Dzionek, J. Schmitz,
and D.N. Hart. 2002. Characterization of human blood dendritic cell
subsets. Blood. 100:4512–4520.
26. Weng, W.K., and R. Levy. 2003. Two immunoglobulin G fragment
C receptor polymorphisms independently predict response to rituximab
in patients with follicular lymphoma. J. Clin. Oncol. 21:3940–3947.
27. Wu, J., J.C. Edberg, P.B. Redecha, V. Bansal, P.M. Guyre, K.
Coleman, J.E. Salmon, and R.P. Kimberly. 1997. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J. Clin. Invest. 100:1059–1070.
28. Charo, I.F., and R.M. Ransohoff. 2006. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med.
354:610–621.
29. McGaha, T.L., B. Sorrentino, and J.V. Ravetch. 2005. Restoration of
tolerance in lupus by targeted inhibitory receptor expression. Science.
307:590–593.
30. Kortylewski, M., M. Kujawski, T. Wang, S. Wei, S. Zhang, S. PilonThomas, G. Niu, H. Kay, J. Mule, W.G. Kerr, et al. 2005. Inhibiting
Stat3 signaling in the hematopoietic system elicits multicomponent
antitumor immunity. Nat. Med. 11:1314–1321.

